Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: Rationale, Technique, and Results

A. Larson, L. Savastano, S. Rammos, W. Brinjikji
{"title":"Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: Rationale, Technique, and Results","authors":"A. Larson, L. Savastano, S. Rammos, W. Brinjikji","doi":"10.1097/01.CNE.0000695020.96579.55","DOIUrl":null,"url":null,"abstract":"rosurgical condition that has a poor natural history. With an inhospital mortality of 16.7%, 1-year mortality of 32%, and only 21.1% of admitted patients returning home, cSDH remains a disabling and deadly disease. The incidence of cSDH greatly increases with age, with some estimates being as high as 18 per 100,000 individuals between the ages of 71 and 80 years. With an aging population and increased use of antiplatelet and anticoagulation medications, the incidence of cSDH is expected to exceed 60,000 new cases per year by the year 2030. Management strategies for cSDH vary widely and are subject to provider and institutional preferences. Traditional management avenues for cSDH have involved conservative management and open surgery. Conservative management has included observation, the use of corticosteroids, statins, osmotically active agents, platelet-activating factor inhibitors, and plasminogen activator inhibitors. Statins, in particular, have been demonstrated to be beneficial for patients with cSDH in recent randomized clinical trials. Surgical management includes options such as twist drill craniostomy at the bedside and open surgical drainage via burr holes or formal craniotomy. In a randomized clinical trial performed in 2009, the use of drains after burr hole drainage was associated with reduced recurrence and mortality at 6 months, thereby justifying the use of drains after burr hole drainage of cSDH. In general, patients who are asymptomatic or have minor symptoms with smaller hematoma volumes typically warrant conservative management, whereas patients with more severe symptoms and larger hematoma volumes require operative intervention. The success rate of each method in resolving the hematoma is variable, although surgical intervention is generally favorable in this regard and offers the advantage of an immediate decompressive effect. However, the recurrence rate of cSDH even after surgical evacuation is variable and may be as high as 37% by some estimates.","PeriodicalId":91465,"journal":{"name":"Contemporary neurosurgery","volume":"42 1","pages":"1 - 6"},"PeriodicalIF":0.0000,"publicationDate":"2020-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.CNE.0000695020.96579.55","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contemporary neurosurgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.CNE.0000695020.96579.55","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

rosurgical condition that has a poor natural history. With an inhospital mortality of 16.7%, 1-year mortality of 32%, and only 21.1% of admitted patients returning home, cSDH remains a disabling and deadly disease. The incidence of cSDH greatly increases with age, with some estimates being as high as 18 per 100,000 individuals between the ages of 71 and 80 years. With an aging population and increased use of antiplatelet and anticoagulation medications, the incidence of cSDH is expected to exceed 60,000 new cases per year by the year 2030. Management strategies for cSDH vary widely and are subject to provider and institutional preferences. Traditional management avenues for cSDH have involved conservative management and open surgery. Conservative management has included observation, the use of corticosteroids, statins, osmotically active agents, platelet-activating factor inhibitors, and plasminogen activator inhibitors. Statins, in particular, have been demonstrated to be beneficial for patients with cSDH in recent randomized clinical trials. Surgical management includes options such as twist drill craniostomy at the bedside and open surgical drainage via burr holes or formal craniotomy. In a randomized clinical trial performed in 2009, the use of drains after burr hole drainage was associated with reduced recurrence and mortality at 6 months, thereby justifying the use of drains after burr hole drainage of cSDH. In general, patients who are asymptomatic or have minor symptoms with smaller hematoma volumes typically warrant conservative management, whereas patients with more severe symptoms and larger hematoma volumes require operative intervention. The success rate of each method in resolving the hematoma is variable, although surgical intervention is generally favorable in this regard and offers the advantage of an immediate decompressive effect. However, the recurrence rate of cSDH even after surgical evacuation is variable and may be as high as 37% by some estimates.
脑膜中动脉栓塞治疗慢性硬膜下血肿:原理、技术和结果
有不良自然病史的神经外科疾病。cSDH的住院死亡率为16.7%,1年死亡率为32%,只有21.1%的入院患者回家,它仍然是一种致残和致命的疾病。cSDH的发病率随着年龄的增长而大大增加,一些估计在71岁至80岁之间高达十万分之十八。随着人口老龄化以及抗血小板和抗凝药物使用的增加,预计到2030年,cSDH的发病率将超过每年60000例。cSDH的管理策略差异很大,并取决于提供商和机构的偏好。cSDH的传统管理途径包括保守管理和开放手术。保守治疗包括观察、使用皮质类固醇、他汀类药物、渗透活性剂、血小板活化因子抑制剂和纤溶酶原激活剂抑制剂。在最近的随机临床试验中,他汀类药物尤其被证明对cSDH患者有益。手术管理包括在床边进行麻花钻开颅术,以及通过毛刺孔或正式开颅术进行开放式手术引流。在2009年进行的一项随机临床试验中,毛刺孔引流术后使用引流管可降低6个月时的复发率和死亡率,从而证明在cSDH的毛刺孔引流后使用引流器是合理的。一般来说,无症状或症状轻微、血肿体积较小的患者通常需要保守治疗,而症状更严重、血肿体积较大的患者则需要手术干预。每种方法解决血肿的成功率各不相同,尽管手术干预在这方面通常是有利的,并且具有立即减压的优点。然而,即使在手术后,cSDH的复发率也是可变的,据估计可能高达37%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信